| Name | Title | Contact Details |
|---|
X4 Pharmaceuticals (Nasdaq: XFOR) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company`s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4`s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavorixafor in Severe Congenital Neutropenia (SCN) and Waldenström`s macroglobulinemia (WM) in 2019. The company was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria.
Kyowa Kirin Co., Ltd.
ParaPRO is a Carmel, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ParagonRx is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Spectrum`s core mission is to bring pharmaceutical products to patients for unmet medical needs. To this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. Spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-Hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (ALL) and one for multiple myeloma. There are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.